Announcements
- Ardelyx to Report Second Quarter 2024 Financial Results on August 1, 2024
- Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines
- To Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA
- Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines
- Ardelyx, Inc. Reports Employment Inducement Grants
- Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference
- Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
- Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
- Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
- Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update
More ▼
Key statistics
On Friday, Ardelyx Inc (41X:FRA) closed at 4.97, 60.71% above the 52 week low of 3.09 set on Oct 16, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.97 |
---|---|
High | 4.97 |
Low | 4.97 |
Bid | 4.97 |
Offer | 5.09 |
Previous close | 5.12 |
Average volume | 7.06k |
---|---|
Shares outstanding | 233.98m |
Free float | 229.99m |
P/E (TTM) | -- |
Market cap | 1.31bn USD |
EPS (TTM) | -0.2883 USD |
Data delayed at least 15 minutes, as of Jul 26 2024 07:05 BST.
More ▼